Erivedge
What Erivedge is used for
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Erivedge
- Active substance
- vismodegib
- Disease area
- Carcinoma, Basal Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX43
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2013
Official information
In the USA
Same active substance: Erivedge
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Erivedge used for?
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
What is the active substance in Erivedge?
Erivedge contains vismodegib.
Who makes Erivedge?
The EU marketing authorisation holder is Roche Registration GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU